- Home
- XPON vs VIVS Comparison
XPON vs VIVS Comparison
Compare XPON & VIVS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- XPON
- VIVS
- Stock Information
- Founded
- XPON 2016
- VIVS 2007
- Country
- XPON United States
- VIVS United States
- Employees
- XPON N/A
- VIVS N/A
- Industry
- XPON Electronic Components
- VIVS Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- XPON Technology
- VIVS Health Care
- Exchange
- XPON Nasdaq
- VIVS Nasdaq
- Market Cap
- XPON 2.8M
- VIVS 3.6M
- IPO Year
- XPON 2022
- VIVS N/A
- Fundamental
- Price
- XPON $0.91
- VIVS $1.80
- Analyst Decision
- XPON
- VIVS
- Analyst Count
- XPON 0
- VIVS 0
- Target Price
- XPON N/A
- VIVS N/A
- AVG Volume (30 Days)
- XPON 343.0K
- VIVS 137.3K
- Earning Date
- XPON 05-15-2025
- VIVS 06-06-2025
- Dividend Yield
- XPON N/A
- VIVS N/A
- EPS Growth
- XPON N/A
- VIVS N/A
- EPS
- XPON N/A
- VIVS N/A
- Revenue
- XPON $6,702,411.00
- VIVS $122,000.00
- Revenue This Year
- XPON $61.26
- VIVS $59.08
- Revenue Next Year
- XPON N/A
- VIVS $18.24
- P/E Ratio
- XPON N/A
- VIVS N/A
- Revenue Growth
- XPON 23.07
- VIVS N/A
- 52 Week Low
- XPON $0.60
- VIVS $1.56
- 52 Week High
- XPON $190.00
- VIVS $21.96
- Technical
- Relative Strength Index (RSI)
- XPON 51.65
- VIVS N/A
- Support Level
- XPON $0.68
- VIVS N/A
- Resistance Level
- XPON $0.87
- VIVS N/A
- Average True Range (ATR)
- XPON 0.12
- VIVS 0.00
- MACD
- XPON -0.00
- VIVS 0.00
- Stochastic Oscillator
- XPON 58.96
- VIVS 0.00
About XPON Expion360 Inc.
Expion360 Inc is focused on the design, assembly, manufacturing, and sales of lithium iron phosphate (LiFePO4) batteries and supporting accessories for recreational vehicles (RV's) and marine applications with plans to expand into home energy storage products and industrial applications. Its product offerings include some of the minimal-footprint batteries in the RV & Marine industry.
About VIVS VivoSim Labs Inc. Common Stock
VivoSim Labs Inc formerly, Organovo Holdings Inc is a biotechnology company focused on developing FXR314 in inflammatory bowel disease (IBD), including ulcerative colitis (UC), based on demonstration of clinical promise in three-dimensional (3D) human tissues as well as preclinical data. FXR is a mediator of gastrointestinal and liver diseases.